

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940

[] Check this box if no longer subject of Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person

Handford, Ronald L.

(Last) (First) (Middle)

3432 W. 13th Avenue

(Street)

Vancouver, British Columbia Canada V6R 2S1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

GeneMax Corp. "GMXX"

3. IRS or Social Security Number of Reporting Person (Voluntary)

4. Statement for Month/Year

September 23, 2002

5. If Amendment, Date of Original (Month/Year)

6. Relationship of Reporting Person to Issuer
(Check all applicable)

[X] Director [] 10% Owner
[X] Officer (give title below) [] Other (specify below)

President/Chief Executive Officer

Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (mm/dd/yy)	3. Transaction Code (Instr. 8) Code V	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4)	6. Owner- ship Form: Direct (D) or Indirect (I) (Instr.4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Amount	(A) or (D)	Price			
Common Stock \$0.001 par value	7/15/02	P/K	150,000	A	*	908,000	D	n/a
Common Stock \$0.001 par value	7/15/02	J	8,000	A	\$6,000	908,000	D	n/a
Common Stock \$0.001 par value	7/15/02	P/K	100,000	A	\$100,000	908,000	I	**

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly

* See attachment A
** See attachment B

Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conver- sion of Exer- cise Price of Deriv- ative Secur- ity	3. Trans- action Date (Month/ Day/ Year)	4. Trans- action Code (Instr. 8) ----- Code V	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) ----- (A) (D)	6. Date Exercisable and Expiration Date (Month/Day/Year) ----- Date Expira- tion Exer- tion Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4) ----- Amount or Number of Shares	8. Price of Deriv- ative Secur- ity (Instr. 5) *	9. Number of Deriv- ative Secur- ities Bene- ficially Owned at End Month (Instr. 4)	10. Owner- ship of Deriv- ative Secur- ity: Direct (D) or In- direct (I) (Instr. 4)	11. Nature of In- direct Bene- ficial Owner- ship (Instr. 4)	
Warrant	\$0.75	07/15/02	J	8,000	07/15/02	06/01/06	Common Stock	8,000	\$6,000	8,000	D	n/a

Explanation of Responses:

/s/ Ronald L. Handford

September 23, 2002

**Signature of Reporting Person

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedures.

ATTACHMENT A TO FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
FOR RONALD L. HANDFORD

On May 9, 2002, effective July 15, 2002, Eduverse.com, a Nevada corporation now known as "GeneMax Corp." (the "Company"), GeneMax Pharmaceuticals Inc., a Delaware corporation ("GeneMax Pharmaceuticals"), the shareholders of GeneMax Pharmaceuticals (the "GeneMax Shareholders"), and Investor Communications International, Inc., a Washington corporation ("ICI") entered into a share exchange agreement (the "Share Exchange Agreement"). In accordance with the terms of the Share Exchange Agreement and the securities laws of Canada, a Directors' Circular dated July 15, 2002 (the "Directors' Circular") was distributed to certain management, insiders and directors of GeneMax Pharmaceuticals (the "Canadian GeneMax Shareholders"). As of the date of this Form 4, the Company has consummated and finalized the acquisition of GeneMax Pharmaceuticals.

Pursuant to the terms of the Share Exchange Agreement and the Directors' Circular, the Company has acquired from the GeneMax Shareholders up to approximately one hundred percent (100%) of the issued and outstanding shares of common stock of GeneMax Pharmaceuticals. In accordance with the terms of the Share Exchange Agreement, the Directors' Circular and related settlement agreements, the Company was required to issue shares of its restricted common stock as follows: (i) approximately 6,411,304 shares of restricted common stock to the GeneMax Shareholders in proportion to their respective holdings in GeneMax Pharmaceuticals; (ii) approximately 4,479,001 shares of restricted common stock to Canadian GeneMax Shareholders pursuant to the terms of the Directors' Circular; (iii) 181,660 shares of restricted common stock to certain creditors of GeneMax Pharmaceuticals at \$0.75 per share for settlement of an aggregate debt in the amount of \$136,245; (iv) 188,154 shares of restricted common stock to certain creditors of GeneMax Pharmaceuticals at \$1.00 per share for settlement of an aggregate debt in the amount of \$188,154; and (v) 200,000 shares of restricted common stock to a third party.

As of the date of this Form 4, the Company has issued an aggregate of 11,460,119 shares of its restricted common stock. Certain shares were issued in accordance with the terms and provisions of warrant agreements pursuant to which the holder thereof has the right to convert such warrant into shares of common stock on a one-to-one basis at either the rate of \$0.75 per share or \$1.00 per share. As of the date of this Form 4, there are an aggregate of (i) 277,500 warrants issued and outstanding which may be converted into 277,500 shares of common stock at the rate of \$1.00 per share expiring December 1, 2005; (ii) 175,000 warrants issued and outstanding which may be converted into 175,000 shares of common stock at the rate of \$1.00 per share expiring May 1, 2006; and (iii) 181,660 warrants issued and outstanding which may be converted into 181,660 shares of common stock at the rate of \$0.75 per share expiring May 1, 2006.

An aggregate offering price of \$2,792,976.50 was determined as follows. For purposes of valuation of the shares of common stock issued in accordance with the terms of the Share Exchange Agreement, the aggregate offering price of \$2,204,231.50 was determined as follows: (i) \$8,100.00 for 8,100,000 shares of common stock issued at \$0.001 per share; (ii) \$1,336,482.00 for 2,227,470 shares of common stock issued at \$0.60 per share; (iii) \$82,750.50 for 110,334 shares of common stock issued at \$0.75 per share; (iv) \$452,500.00 for 452,500 shares of common stock issued at \$1.00 per share; (v) \$136,245.00 for 181,660 shares of common stock issued at \$0.75 per share pursuant to debt settlement; and (vi) \$188,154.00 for 188,154 shares of common stock issued at \$1.00 per share pursuant to debt settlement. For purposes of valuation of the warrants issued, an aggregate offering price of \$588,745 was determined as follows: (i) \$136,245.00 for 181,660 warrants exercisable into 181,660 shares of common stock at \$0.75 per share; and (ii) \$452,500 for 452,500 warrants exercisable into 452,500 shares of common stock at \$1.00 per share.

The price for the issuance of shares of common stock as reported herein is as follows: (i) \$150.00 for the issuance of 150,000 shares of common stock at \$0.001 per share to Ronald L. Handford; (ii) \$6,000.00 for the issuance of 8,000 shares of common stock at \$0.75 per share to Ronald L. Handford for settlement of debt; and (iii) \$100,000.00 for the issuance of 100,000 shares of common stock at \$1.00 per share to Handford Management Inc.

The price for the warrants was determined in accordance with the provisions of the warrant agreement.

ATTACHMENT B TO FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
FOR RONALD L. HANDFORD

Of the 908,000 shares of common stock reported as beneficially owned by Ronald L. Handford: (i) 100,000 shares were issued of record to Handford Management Inc., over which Ronald L. Handford has shared voting and disposition rights; (ii) 325,000 shares were issued of record to Aberdeen Holdings Limited, over which Ronald L. Handford has sole disposition rights; and (iii) 325,000 shares were issued of record to Latitude 32 Holdings Ltd., over which Ronald L. Handford has sole disposition rights.